Guardant Health, Inc. (GH)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$185.31+1.49%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put GH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue growth is accelerating — up about 43% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 33% in its worst 12-month stretch.
View RiskGH’s case rests on revenue growth, though unprofitability leaves earnings quality unassessable. Revenue grew 44% year over year in Q2 FY2026, and the latest earnings beat. GH trades at 21× sales versus a 5× peer median, above its own 19× historical multiple. The price reflects less growth than our forecast, despite that premium. The premium must be earned; our model puts next-quarter miss probability near 24%. Management is running behind on a stated commitment. Peer multiples imply a price about 7% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. GH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering GH (as of Oct 2026).
Based on 15 Wall Street analysts offering 12-month price targets for GH in the last 4 months.
Continue this research
Compare GH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put GH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Achieve 36% to 38% revenue growth in 2026
Patent judgment could hinder revenue growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $185.31
The last 12 months of price, then the range of analyst 12-month targets from today’s $185.31.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Patent infringement could impact financial stability and growth.
Advances: Expand Shield screening test volume and revenue
FDA approval boosts Shield test volume and revenue potential.
Reaffirmation of buy rating supports positive outlook.
New buy rating indicates confidence in growth potential.
Price target increase reflects positive sentiment post-FDA approval.
FDA clearance significantly enhances growth prospects.
Advances: Achieve 32% to 34% revenue growth in 2026
Strong revenue growth supports 2026 targets.